Tianyu Corporation: Wholly owned subsidiary Meiashatan Potassium Tablets obtain drug registration certificate.

Tianyu Co., Ltd. announced that its wholly-owned subsidiary Nuode Pharmaceutical recently received the Drug Registration Certificate for Telmisartan Potassium Tablets issued by the National Medical Products Administration, with specifications of 40mg and 80mg, valid until June 29, 2031, indicated for the treatment of primary hypertension in adults. The sales of this drug in domestic sample hospitals and physical pharmacies are expected to be around 160 million yuan in 2025. As of May 31, 2026, the company and its subsidiaries have accumulated research and development investment of approximately 4.4541 million yuan for this product. The approval of this product is expected to increase the company's formulation business income, but the production, sales, and profit levels have uncertainties.